About Mac Labs Limited
Mac Labs Limited offers products and services including APIs and Formulations.
- SectorsHealthcare
- Email••••••••
- Legal Name Mac Labs Limited
- Date of Incorporation 13 Nov, 2018
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹13.46 Cr
FY 2024 · -54% YoY
- Net Profit₹47.7 Lakh
FY 2024 · 4% margin
- EBITDA₹1.63 Cr
FY 2024 · 12% margin
Associated legal entities of Mac Labs Limited
Mac Labs Limited operates through Mac Labs Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Mac Labs Limited CIN U74999TG2018PLC128275 | Active | 13 Nov 2018 | Hyderabad, Telangana | ₹13.5 Cr | – | 3 | View details |
Products & Services of Mac Labs Limited
Mac Labs Limited offers a comprehensive portfolio of products and services, including APIs and Formulations.
Active ingredients and drug intermediates are produced under cGMP conditions for own marketing and custom manufacturing purposes.
Finished dosage forms such as tablets, capsules, and modified release pellets are manufactured, focusing on immediate and modified release solid forms.
Board of directors of Mac Labs Limited (Mac Labs Limited)
Mac Labs Limited is the primary company behind Mac Labs Limited. The board of Mac Labs Limited currently have 3 directors; the longest-serving is Soreddy Divya, appointed in 2018.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Soreddy Divya DIN 08261988 | Director | 13 Nov 2018 | 7 yrs 10 mo | Mac Labs Limited |
| Laxmi Soreddy Sankar DIN 07505586 | Director | 13 Nov 2018 | 7 yrs 10 mo | Mac Labs Limited |
| Soreddy Shiva Sankar Reddy DIN 07505584 | Director | 13 Nov 2018 | 7 yrs 10 mo | Mac Labs Limited |
Financials of Mac Labs Limited
Figures of Mac Labs Limited, the primary company behind Mac Labs Limited, for FY 2024. Revenue was ₹13.46 Cr (-54% year on year). Net profit was ₹47.7 Lakh (4% margin). EBITDA was ₹1.63 Cr (12% margin). Revenue has grown at a compounded annual rate of +73% over three years.
- ₹13.46 CrRevenue · FY 2024 · -54% YoY
- ₹47.7 LakhNet profit · 4% margin
- ₹1.63 CrEBITDA · 12% margin
- ₹10 LakhPaid-up capital
- +73%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Mac Labs Limited are on its company page.
Detailed financial statements for Mac Labs Limited
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Mac Labs Limited
10 companies that operate in the same segment as Mac Labs Limited (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Mac Labs Limited
The primary company behind Mac Labs Limited, Mac Labs Limited, reported revenue of ₹13.46 Cr for FY 2024, down 54% year on year.
Mac Labs Limited is identified as a manufacturer of active pharmaceutical ingredients and drug intermediates under cGMP conditions, with facilities situated in Bidar and Hyderabad, India. Finished dosage forms like tablets and capsules are produced, alongside clinical research services that include BABE studies for global customers. Compliance with WHO and GMP standards is maintained, and the company engages in contract manufacturing and supply to domestic and international markets. Ethical practices and quality management systems are emphasized in its operations, contributing to its recognition in the pharmaceutical industry.
Mac Labs Limited offers APIs and Formulations.
Mac Labs Limited operates through Mac Labs Limited.
The legal entities of Mac Labs Limited currently have 3 directors, including Soreddy Divya, Laxmi Soreddy Sankar, Soreddy Shiva Sankar Reddy.